JP2014524479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524479A5 JP2014524479A5 JP2014527312A JP2014527312A JP2014524479A5 JP 2014524479 A5 JP2014524479 A5 JP 2014524479A5 JP 2014527312 A JP2014527312 A JP 2014527312A JP 2014527312 A JP2014527312 A JP 2014527312A JP 2014524479 A5 JP2014524479 A5 JP 2014524479A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- alkyl
- aryl
- membered
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- 125000003118 aryl group Chemical group 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 32
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 29
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 28
- 125000001188 haloalkyl group Chemical group 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 206010060862 Prostate cancer Diseases 0.000 claims description 18
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 18
- 210000002966 serum Anatomy 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 229940124530 sulfonamide Drugs 0.000 claims description 16
- 150000003456 sulfonamides Chemical class 0.000 claims description 16
- 238000009167 androgen deprivation therapy Methods 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 14
- 229960003604 testosterone Drugs 0.000 claims description 14
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 12
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 12
- 210000000988 bone and bone Anatomy 0.000 claims description 12
- 230000003247 decreasing effect Effects 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 230000001394 metastastic effect Effects 0.000 claims description 9
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 125000004982 dihaloalkyl group Chemical group 0.000 claims description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 125000004385 trihaloalkyl group Chemical group 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 229940127557 pharmaceutical product Drugs 0.000 claims description 7
- 208000010392 Bone Fractures Diseases 0.000 claims description 6
- 206010017076 Fracture Diseases 0.000 claims description 6
- 208000033830 Hot Flashes Diseases 0.000 claims description 6
- 206010060800 Hot flush Diseases 0.000 claims description 6
- 210000000577 adipose tissue Anatomy 0.000 claims description 6
- 201000000079 gynecomastia Diseases 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 5
- 102000006395 Globulins Human genes 0.000 claims description 2
- 108010044091 Globulins Proteins 0.000 claims description 2
- 239000003163 gonadal steroid hormone Substances 0.000 claims description 2
- 238000011474 orchiectomy Methods 0.000 claims description 2
- 239000003270 steroid hormone Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 32
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 40
- 239000003098 androgen Substances 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/215,679 | 2011-08-23 | ||
| US13/215,679 US9427418B2 (en) | 2009-02-23 | 2011-08-23 | Estrogen receptor ligands and methods of use thereof |
| PCT/US2012/052141 WO2013043304A1 (en) | 2009-02-23 | 2012-08-23 | Estrogen receptor ligands and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014524479A JP2014524479A (ja) | 2014-09-22 |
| JP2014524479A5 true JP2014524479A5 (https=) | 2015-10-08 |
Family
ID=48444651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527312A Pending JP2014524479A (ja) | 2011-08-23 | 2012-08-23 | エストロゲン受容体リガンドおよびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2747562A4 (https=) |
| JP (1) | JP2014524479A (https=) |
| KR (1) | KR20140064906A (https=) |
| CN (1) | CN103957706A (https=) |
| AU (1) | AU2012312902B2 (https=) |
| CA (1) | CA2845890A1 (https=) |
| IL (1) | IL231070A0 (https=) |
| IN (1) | IN2014DN01959A (https=) |
| MX (1) | MX2014002105A (https=) |
| RU (1) | RU2014111060A (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL273195B2 (en) * | 2017-09-27 | 2024-04-01 | Targimmune Therapeutics Ag | Castration-resistant prostate cancer |
| EP3917519A1 (en) * | 2019-01-30 | 2021-12-08 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| JP2022523746A (ja) * | 2019-02-01 | 2022-04-26 | フォンダツィオーネ・ペア・リスチチュート・オンコロジコ・ディ・リチェルカ・（イオエッレ） | 去勢抵抗性前立腺がんを処置する方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8546451B2 (en) * | 2005-11-28 | 2013-10-01 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| EA201500845A1 (ru) * | 2005-11-28 | 2016-04-29 | Джи Ти Икс, ИНК. | Агенты, связывающиеся с ядерными рецепторами |
| US8158828B2 (en) * | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
| JP5611991B2 (ja) * | 2009-02-23 | 2014-10-22 | ジーティーエックス・インコーポレイテッド | Ａｄｔのための医薬の製造におけるエストロゲン受容体リガンドの使用方法 |
-
2012
- 2012-08-23 EP EP12834287.0A patent/EP2747562A4/en not_active Withdrawn
- 2012-08-23 CN CN201280051979.4A patent/CN103957706A/zh active Pending
- 2012-08-23 JP JP2014527312A patent/JP2014524479A/ja active Pending
- 2012-08-23 KR KR1020147007549A patent/KR20140064906A/ko not_active Withdrawn
- 2012-08-23 CA CA2845890A patent/CA2845890A1/en not_active Abandoned
- 2012-08-23 RU RU2014111060/15A patent/RU2014111060A/ru not_active Application Discontinuation
- 2012-08-23 IN IN1959DEN2014 patent/IN2014DN01959A/en unknown
- 2012-08-23 MX MX2014002105A patent/MX2014002105A/es unknown
- 2012-08-23 AU AU2012312902A patent/AU2012312902B2/en not_active Ceased
-
2014
- 2014-02-20 IL IL231070A patent/IL231070A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7516472B2 (ja) | 癌を治療するための方法 | |
| ES2877629T3 (es) | Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer | |
| US9205086B2 (en) | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor | |
| JP2013501731A5 (https=) | ||
| US20140051665A1 (en) | Prostate cancer therapy with hsp90 inhibitory compounds | |
| US20130171105A1 (en) | Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor | |
| JP2014502641A5 (https=) | ||
| JP2014518848A (ja) | 糖尿病を治療するための選択的アンドロゲン受容体調節因子 | |
| WO2012162293A1 (en) | Combination therapy of hsp90 inhibitory compounds with mek inhibitors | |
| CA2853799A1 (en) | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors | |
| JP2016506916A5 (https=) | ||
| JP2016040288A5 (https=) | ||
| WO2013006864A2 (en) | Treating cancer with hsp90 inhibitory compounds | |
| EP2714033A1 (en) | Combination therapy of hsp90 inhibitory compounds with chk inhibitors | |
| WO2012096919A1 (en) | Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors | |
| CN115671114A (zh) | 用于肿瘤治疗的11-脱氧皮质醇的17α,21-二酯 | |
| RU2011137324A (ru) | Лиганды рецепторов эстрогенов и способы их применения | |
| JP2014529584A5 (https=) | ||
| JP2014524479A5 (https=) | ||
| JP2016526049A5 (https=) | ||
| JP2019516726A5 (https=) | ||
| RU2014111060A (ru) | Лиганды рецептора эстрогена и способы их применения | |
| RU2006123939A (ru) | Лечение остеопороза, связанного с терапией ингибиторами ароматазы | |
| JP2017527627A (ja) | 喫煙者における非小細胞肺癌の治療のための、カルボプラチンおよびパクリタキセルと併用したベリパリブ | |
| JP2018507880A5 (https=) |